Stockscreener 앱 받기
34.05
1.33%
-0.46
시간 외 거래:
34.06
0.01
+0.03%
전일 마감가:
$34.51
열려 있는:
$34.735
하루 거래량:
6.01M
Relative Volume:
1.02
시가총액:
$24.49B
수익:
$8.26M
순이익/손실:
$-397.91M
주가수익비율:
-67.61
EPS:
-0.5036
순현금흐름:
$-758.56M
1주 성능:
-1.33%
1개월 성능:
+8.34%
6개월 성능:
+48.17%
1년 성능:
+197.64%
1일 변동 폭
$33.96
$35.09
1주일 범위
$33.56
$35.13
52주 변동 폭
$10.90
$37.00
Roivant Sciences Ltd Stock (ROIV) Company Profile
명칭
Roivant Sciences Ltd
전화
441-295-5950
주소
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
34.05 | 24.82B | 8.26M | -397.91M | -758.56M | -0.5036 |
VRTX
Vertex Pharmaceuticals Inc
|
480.50 | 123.26B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.15 | 70.94B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.19 | 53.84B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
180.39 | 39.58B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
272.67 | 35.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-20 | 개시 | Bernstein | Outperform |
| 2025-09-02 | 개시 | Citigroup | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-01-05 | 개시 | Piper Sandler | Overweight |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-17 | 개시 | Guggenheim | Buy |
| 2023-06-08 | 개시 | BofA Securities | Neutral |
| 2022-10-27 | 개시 | JP Morgan | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 개시 | Goldman | Buy |
| 2021-11-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-28 | 개시 | Citigroup | Buy |
| 2021-10-26 | 개시 | Cowen | Outperform |
| 2021-10-26 | 개시 | Jefferies | Buy |
| 2021-10-26 | 개시 | Truist | Buy |
모두보기
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
Why is Billionaire Joe Edelman Bullish on Roivant Sciences (ROIV) - Kavout | AI
Pfizer, BioNTech face global patent suits from Arbutus, Roivant over COVID vaccine tech - Seeking Alpha
Roivant unit Genevant, Arbutus file patent infringement suits against Pfizer, BioNTech over LNP technology - Bitget
ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring the 9.47% Upside Potential in Biotech Innovation - DirectorsTalk Interviews
Roivant Sciences (ROIV) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Roivant’s Gline: From spin-cos to commercial conviction - BioCentury
Roivant Sciences (ROIV) Climbs 2%: Biotech Stock Tests Key Resistance Near $38.65Moving Average Ribbon - dars.gov.et
Responsive Playbooks and the ROIV Inflection - Stock Traders Daily
Roivant Sciences (ROIV) TD Cowen 45th Annual Healthcare Conference Summary - Quartr
Roivant Sciences stock hits all-time high at 35.92 USD By Investing.com - Investing.com Nigeria
Roivant Sciences stock hits all-time high at 35.92 USD - Investing.com
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years? - Yahoo Finance
Roivant Sciences Ltd. (ROIV) Stock Analysis: Potential Upside Amidst Biotech Innovations - DirectorsTalk Interviews
If You Invested $1,000 in Roivant Sciences (ROIV) - Stock Titan
ROIVRoivant Sciences Ltd Dividends - Finviz
Roivant Sciences Insider Sold Shares Worth $610,252, According to a Recent SEC Filing - Moomoo
Roivant Sciences (ROIV) director exercises options, sells 10,000 common shares - Stock Titan
Roivant Sciences (ROIV) Left Key Russell Indexes, Is It Still 10% Below Fair Value? - simplywall.st
76K Roivant (ROIV) shares withheld for CEO Matthew Gline RSU tax payment - Stock Titan
Roivant Sciences (ROIV) director sells 17,750 shares after exercising options - Stock Titan
Roivant Sciences Insider Sold Shares Worth $56,444,076, According to a Recent SEC Filing - marketscreener.com
Roivant Sciences Insider Sold Shares Worth $49,354,076, According to a Recent SEC Filing - marketscreener.com
Roivant Sciences (ROIV) director-linked entity reports 1.44M-share open-market sale - Stock Titan
Form 144 ROIVANT SCIENCES LTD. For: 30 June - Investing.com UK
Roivant Sciences(ROIV.US) Director Sells US$56.44 Million in Common Stock - Moomoo
Roivant Sciences Director Sold Shares Worth Over $56M - TradingView
Form 144 ROIVANT SCIENCES LTD. For: 30 June By Investing.com - Investing.com Nigeria
Is Roivant Sciences (ROIV) Losing Its Defensive Status or Reframing Its Risk Narrative? - simplywall.st
Roivant Sciences Insider Sold Shares Worth $34,105,000, According to a Recent SEC Filing - Moomoo
Roivant Sciences Ltd.(NasdaqGS: ROIV) dropped from Russell 1000 Value-Defensive Index - marketscreener.com
Roivant Sciences Ltd.(NasdaqGS: ROIV) dropped from Russell 1000 Defensive Index - marketscreener.com
Roivant Sciences Ltd. (ROIV) Stock Analysis: A Biotech Powerhouse with 14.59% Potential Upside - DirectorsTalk Interviews
Roivant Sciences Insider Sold Shares Worth $6,631,268, According to a Recent SEC Filing - Moomoo
Understanding the Setup: (ROIV) and Scalable Risk - Stock Traders Daily
Price to sales forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Enterprise value to revenue forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Enterprise value to revenue forward of Roivant Sciences Ltd. – DUS:87S - TradingView
Enterprise value to EBITDA forward of Roivant Sciences Ltd. – DUS:87S - TradingView
Enterprise value to EBIT forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Form 144 ROIVANT SCIENCES LTD. For: 26 June - Investing.com UK
Form 144 ROIVANT SCIENCES LTD. For: 26 June By Investing.com - Investing.com Nigeria
Price to earnings forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Roivant Sciences(ROIV.US) Officer Sells US$6.63 Million in Common Stock - Moomoo
Roivant (NASDAQ: ROIV) president sells 200K shares, exercises 200K stock options - Stock Titan
Form 144 ROIVANT SCIENCES LTD. For: 25 June - Investing.com UK
Form 144 ROIVANT SCIENCES LTD. For: 25 June By Investing.com - Investing.com South Africa
Roivant Sciences Ltd (ROIV) Institutional Confidence - TradingKey
JNJ Stock Price and Chart — NYSE:JNJ - TradingView
Price to book forward of Roivant Sciences Ltd. – NASDAQ:ROIV - TradingView
Roivant Sciences Ltd (ROIV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.77%
0.74%
자본화:
|
볼륨(24시간):